Clarity Pharmaceuticals (ASX:CU6) is set to advance its SECuRE trial to the phase II cohort expansion phase with no changes to the protocol, following a recommendation by the safety review committee, according to a Thursday filing with the Australian bourse.

The trial evaluates the company's targeted copper theranostic product, 67Cu-SAR-bisPSMA, for the treatment of prostate cancer, the filing said.

The interim results assessed by the committee from nine participants who had evaluable data by Nov. 25, 2025, showed promising efficacy and a favorable safety profile for 67Cu-SAR-bisPSMA.

The trial will continue enrollment in the cohort expansion phase, with recruitment completion expected this year, as per the filing.